Survey of CTX-M-3 extended-spectrum β-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan

Lii Tzu Wu, Mei Fen Tsou, Hwa Jene Wu, Hui E. Chen, Yin Ching Chuang, Wen-Liang Yu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Thirty-four clinical isolates of Serratia marcescens nonsusceptible to cefotaxime were collected from a medical center in middle Taiwan. Confirmatory tests for extended-spectrum β-lactamases (ESBLs) by cefotaxime and ceftazidime ± clavulanic acid using Etest ESBL Screen identified only one ESBL producer; the remaining 33 isolates revealed nondeterminable results, because of off-scale minimum inhibitory concentration (MIC) levels for cefotaxime ± clavulanic acid. Agar microdilution method using broader MIC ranges confirmed 21 ESBL-producers and one non-determinable result, achieving a highly predicting value compared to golden standard by PCR and DNA sequencing analysis, which identified 22 (65%) isolates containing bla CTX-M-3 genes. Only one strain carried concurrent CTX-M-3 and SHV-5 conferring high-level MICs to both cefotaxime (128 μg/mL) and ceftazidime (64 μg/mL). Other enzymatic mechanisms, such as chromosome-encoded AmpC including a novel SRT-2 enzyme, may confer resistance to cefotaxime on the remaining 12 isolates without ESBL bla genes. Thus, it is unreliable to predict the resistance mechanism by antibiogram, and current Etest ESBL Screen tests. Our study highlights expanding efforts to detect ESBLs in S. marcescens are urgently needed in Taiwan.

Original languageEnglish
Pages (from-to)125-129
Number of pages5
JournalDiagnostic Microbiology and Infectious Disease
Volume49
Issue number2
DOIs
Publication statusPublished - Jun 2004
Externally publishedYes

Fingerprint

Serratia marcescens
Cefotaxime
Taiwan
Microbial Sensitivity Tests
Disk Diffusion Antimicrobial Tests
Clavulanic Acid
Ceftazidime
DNA Sequence Analysis
Genes
Agar
Chromosomes
Surveys and Questionnaires
Polymerase Chain Reaction
Enzymes

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

Survey of CTX-M-3 extended-spectrum β-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan. / Wu, Lii Tzu; Tsou, Mei Fen; Wu, Hwa Jene; Chen, Hui E.; Chuang, Yin Ching; Yu, Wen-Liang.

In: Diagnostic Microbiology and Infectious Disease, Vol. 49, No. 2, 06.2004, p. 125-129.

Research output: Contribution to journalArticle

@article{8ce72fbd1c694101b4a33f674011b4ed,
title = "Survey of CTX-M-3 extended-spectrum β-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan",
abstract = "Thirty-four clinical isolates of Serratia marcescens nonsusceptible to cefotaxime were collected from a medical center in middle Taiwan. Confirmatory tests for extended-spectrum β-lactamases (ESBLs) by cefotaxime and ceftazidime ± clavulanic acid using Etest ESBL Screen identified only one ESBL producer; the remaining 33 isolates revealed nondeterminable results, because of off-scale minimum inhibitory concentration (MIC) levels for cefotaxime ± clavulanic acid. Agar microdilution method using broader MIC ranges confirmed 21 ESBL-producers and one non-determinable result, achieving a highly predicting value compared to golden standard by PCR and DNA sequencing analysis, which identified 22 (65{\%}) isolates containing bla CTX-M-3 genes. Only one strain carried concurrent CTX-M-3 and SHV-5 conferring high-level MICs to both cefotaxime (128 μg/mL) and ceftazidime (64 μg/mL). Other enzymatic mechanisms, such as chromosome-encoded AmpC including a novel SRT-2 enzyme, may confer resistance to cefotaxime on the remaining 12 isolates without ESBL bla genes. Thus, it is unreliable to predict the resistance mechanism by antibiogram, and current Etest ESBL Screen tests. Our study highlights expanding efforts to detect ESBLs in S. marcescens are urgently needed in Taiwan.",
author = "Wu, {Lii Tzu} and Tsou, {Mei Fen} and Wu, {Hwa Jene} and Chen, {Hui E.} and Chuang, {Yin Ching} and Wen-Liang Yu",
year = "2004",
month = "6",
doi = "10.1016/j.diagmicrobio.2004.02.004",
language = "English",
volume = "49",
pages = "125--129",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Survey of CTX-M-3 extended-spectrum β-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan

AU - Wu, Lii Tzu

AU - Tsou, Mei Fen

AU - Wu, Hwa Jene

AU - Chen, Hui E.

AU - Chuang, Yin Ching

AU - Yu, Wen-Liang

PY - 2004/6

Y1 - 2004/6

N2 - Thirty-four clinical isolates of Serratia marcescens nonsusceptible to cefotaxime were collected from a medical center in middle Taiwan. Confirmatory tests for extended-spectrum β-lactamases (ESBLs) by cefotaxime and ceftazidime ± clavulanic acid using Etest ESBL Screen identified only one ESBL producer; the remaining 33 isolates revealed nondeterminable results, because of off-scale minimum inhibitory concentration (MIC) levels for cefotaxime ± clavulanic acid. Agar microdilution method using broader MIC ranges confirmed 21 ESBL-producers and one non-determinable result, achieving a highly predicting value compared to golden standard by PCR and DNA sequencing analysis, which identified 22 (65%) isolates containing bla CTX-M-3 genes. Only one strain carried concurrent CTX-M-3 and SHV-5 conferring high-level MICs to both cefotaxime (128 μg/mL) and ceftazidime (64 μg/mL). Other enzymatic mechanisms, such as chromosome-encoded AmpC including a novel SRT-2 enzyme, may confer resistance to cefotaxime on the remaining 12 isolates without ESBL bla genes. Thus, it is unreliable to predict the resistance mechanism by antibiogram, and current Etest ESBL Screen tests. Our study highlights expanding efforts to detect ESBLs in S. marcescens are urgently needed in Taiwan.

AB - Thirty-four clinical isolates of Serratia marcescens nonsusceptible to cefotaxime were collected from a medical center in middle Taiwan. Confirmatory tests for extended-spectrum β-lactamases (ESBLs) by cefotaxime and ceftazidime ± clavulanic acid using Etest ESBL Screen identified only one ESBL producer; the remaining 33 isolates revealed nondeterminable results, because of off-scale minimum inhibitory concentration (MIC) levels for cefotaxime ± clavulanic acid. Agar microdilution method using broader MIC ranges confirmed 21 ESBL-producers and one non-determinable result, achieving a highly predicting value compared to golden standard by PCR and DNA sequencing analysis, which identified 22 (65%) isolates containing bla CTX-M-3 genes. Only one strain carried concurrent CTX-M-3 and SHV-5 conferring high-level MICs to both cefotaxime (128 μg/mL) and ceftazidime (64 μg/mL). Other enzymatic mechanisms, such as chromosome-encoded AmpC including a novel SRT-2 enzyme, may confer resistance to cefotaxime on the remaining 12 isolates without ESBL bla genes. Thus, it is unreliable to predict the resistance mechanism by antibiogram, and current Etest ESBL Screen tests. Our study highlights expanding efforts to detect ESBLs in S. marcescens are urgently needed in Taiwan.

UR - http://www.scopus.com/inward/record.url?scp=2942536009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942536009&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2004.02.004

DO - 10.1016/j.diagmicrobio.2004.02.004

M3 - Article

C2 - 15183862

AN - SCOPUS:2942536009

VL - 49

SP - 125

EP - 129

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 2

ER -